

A3
cancel.

[SEQ ID NO:44] SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

A4

66. (Amended) A method of inhibiting viral replication, comprising contacting cells infected with a virus with [human] ovine interferon- τ at a [concentration effective] dosage of at least about 5×10^4 units/day to inhibit viral replication within said cells.

A5
inlc

71. (Amended) A method of claim 66, where said protein contains [the] a sequence selected from the sequences presented as [SEQ ID NO:44] SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

A6

--96. The method of claim 55, wherein said contacting is at a dosage of at least about 5×10^8 units/day.

2 97. The method of claim 66, wherein said contacting is at a dosage of at least about 5×10^8 units/day.--

Remarks

Claims 55 and 66 are amended to recited ovine, rather than human, interferon- τ and to include a lower dosage limitation, as supported on page 58, line 5. Claims 59 and 71 are amended to set forth the sequences directed to ovine interferon- τ , as set forth on pages 16-17.

New claims 96-97 recite a dosage of 5×10^8 units/day, as described in page 58, lines 4-5.

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 324-0880.

Respectfully submitted,

Judy Mohr

Date: 12/22/00

Judy M. Mohr
Registration No. 38,563

Correspondence Address
Customer No. 22918